Vertex COO Stuart Arbuckle on the approval and launch of CASGEVY for sickle cell disease at #ASH23

Stuart Arbuckle describes the approval and launch dynamics of this gene-edited cell therapy, describes who it is for, and comments on the possible long-term direction of the field.